Initiated 2026-10-16 · Price $99.62 (as of 2026-10-16 close, stockanalysis.com) · Mkt cap $7.27bn · Financials / specialty P&C insurance and reinsurance · Model: verified

Rating: Buy — Conviction: High

AXIS has turned into a specialty insurer that earns mid-to-high-teens returns on equity. Operating ROACE was 18.1% in 2025 and 15.9% in H1 2026, and diluted book per share has grown 15 quarters in a row. Yet the stock trades at ~1.2x book and ~7.7x forward earnings, as if the 2023 reserve charge were about to repeat. The softening market (property rates −17% at AXIS in Q2) is real and will compress margins. Even so, a ~93% combined ratio plus a 4.2% portfolio yield still clears a full cost of equity, and that is worth more than today's price.

Conviction tests (3a-v-c): T1 pass (Base +25.2% at +1pp, +72.1% at −1pp) · T2 pass (residual income +44.2%, justified P/BV +45.8%) · T3 pass · T4 pass (no pending deal, ruling or contract event; Q3 results on 2026-10-28 are routine)

The rule gives High. My own read is Medium: the soft market is only two quarters old, and the Base case holds the combined ratio at 93% while property rates fall by double digits.

Model value range vs price
Bear $72.01Base $144.47Bull $229.25Price $99.62

Business overview

AXIS writes specialty insurance (74% of 2025 gross premiums written of $9.64bn) and reinsurance (26%) from Bermuda, the US, London/Lloyd's and Europe. Insurance covers property, casualty (liability, professional, cyber), marine and aviation, A&H, and credit and political risk. A growing set of "new and expanded" lines, plus a small-business channel (ACS), added ~13 points of Q2 insurance growth. Reinsurance is now mostly casualty and specialty treaty, with property-cat in run-off, and it cedes heavily to third-party capital partners. Earnings come down to three things: the insurance combined ratio, earned-premium growth net of growing cessions, and investment income on ~$17.8bn of cash and investments.

Competition

The players that matter in AXIS's core lines are Arch (specialty insurance plus reinsurance), W. R. Berkley (US specialty and E&S casualty), Everest (insurance and reinsurance) and Lloyd's syndicates in property and marine. Competition is showing up through price. Marsh's Q2 2026 index had US property rates −13% (−20% on large cat-exposed programs), the eighth straight quarter of global declines. US casualty was still +7%. AXIS's own figures were property −17% (E&S property −22%), liability +7% and cyber −7% (Q2 call, July 2026). AXIS's response has been to cede more: the property cession rate rose from 30% to 37%, and reinsurance GWP fell 25% in Q2. That protects margin but caps earned-premium growth. The closest listed comparable, Arch, trades at 1.45x book and 10.2x forward earnings (stockanalysis, 2026-10-16).

Bull case

  1. Specialty growth keeps compounding — the new and expanded lines and ACS grow faster than core lines shrink. Insurance GWP rose 15% in Q2. Plays out if casualty rates stay positive and new teams hit plan. Model: npe_growth
  2. Underwriting discipline holds near 90% — G&A falls to the 11% target, the ex-cat accident-year ratio stays near 88%, and short-tail reserve releases continue. FY2025's 89.8% was not a one-off. Plays out if cat activity is normal and casualty reserves stay clean. Model: combined_ratio
  3. Investment income rises — the fixed-maturity book yield (4.8%) is still below market yield (5.1%), so reinvestment lifts the yield toward 4.5%. Plays out if the 10Y stays near 5%. Model: investment_yield

Bear case

  1. The soft market bites — double-digit property rate cuts, a shrinking reinsurance book and new capacity push written premium flat to down. The combined ratio moves to 96–97% before pricing turns. Plays out if Q3/Q4 rate declines widen and casualty rates slow below loss trend. Model: npe_growth, combined_ratio
  2. Casualty reserves repeat 2023 — AXIS took $412mm of adverse development in FY2023. Excess casualty pricing is "behind trend" (CEO, Q2 call), and Q2's releases came only from short-tail lines. Plays out if long-tail development turns adverse. Model: combined_ratio
  3. Yields fall — Fed cuts and weak alternatives take the portfolio yield to ~3.8%. Plays out in a cutting cycle. Model: investment_yield

Valuation & balance sheet

Metric (definition) Current Own history (range or 5y avg) Peers Source, as-of
P/B (price ÷ diluted book per share) 1.23x on $80.67 (6/30); 1.20x aggregator basis Diluted BVPS $46.95 (2022) → $54.06 → $65.27 → $77.20 (2025); historical P/B n/a (unverified) ACGL 1.45x · EG 0.96x · RNR 1.30x · WRB 2.92x Q2 2026 8-K; Q4 2023/2025 releases; stockanalysis 2026-10-16
P/E (forward, consensus) 7.71x n/a (unverified) ACGL 10.20x · EG 6.98x · RNR 8.00x · WRB 15.68x stockanalysis 2026-10-16
Operating ROACE (company definition) 15.9% (H1 2026, annualized) 18.6% (2024), 18.1% (2025) ROE (aggregator TTM): ACGL 19.9% · EG 12.6% · RNR 21.5% · WRB 20.2% Q2 2026 8-K; Q4 2025 release; stockanalysis
Combined ratio 91.5% (H1 2026) 95.8% (2022), 99.9% (2023), 92.3% (2024), 89.8% (2025) n/a Company releases

Model-implied value range (from model-summary.json; insurer, residual income and justified P/BV, midpoints): Bear $72.01 · Base $144.47 · Bull $229.25 per share, i.e. implied returns of −27.7% / +45.0% / +130.1% vs $99.62. These ranges show how the bull and bear drivers translate into value; they are not price targets. The price sits much closer to the Bear case than to Base: the market is pricing something like a 95%+ combined ratio for several years, or a reserve event. Re-rating: today's multiple on the model's own basis is 1.27x FY0 common book ($78.68 per share). Base justified P/B ($145.29) embeds 1.85x (+46%). Residual income ($143.65) embeds 1.83x. The methods agree within 2%, so the upside is one re-rating, toward ACGL's 1.45x and beyond, earned by a ~15% ROE against a 9.4% cost of equity. A tail sensitivity gives $42.61 (−57%). Its drivers: NPE 0%, −5%, −5%, 0%, +1%; combined ratio 97%, 100%, 100%, 98%, 97%; yield 3.5%; other expense $160mm; CoE 11.0%; terminal growth 1.5%.

Balance sheet: debt $1,317.5mm (senior plus junior subordinated notes) and $550mm preferred against $5,953mm common equity at 6/30. Debt/(debt + common book) is 18.5% at FY0. Coverage is ~21.5x pre-tax plus interest over interest, on a placeholder coupon. Liquidity: cash $780mm. Nearest material maturity: n/a (unverified); tranche terms were not retrieved. Ratings: S&P A+ and AM Best A (financial strength, operating subsidiaries, FY2025 10-K).

Model note: built and LibreOffice-verified (2,846 formula cells matched). FY2022–25 historicals come from the Q4 2023 8-K and the Q4 2025 release. EDGAR XBRL endpoints returned empty through the fetch tool, so the filing releases were the fallback. Unverified inputs: none. Assumptions without basis: none. No scenario CHECKs. Pre-tax FY0 is GAAP, but drivers run on an operating basis: other_expense excludes gains and FX and includes ~$37mm pre-tax equivalent of preferred dividends. Diluted shares (73.8mm) are derived from 6/30 common equity ÷ diluted BVPS. The debt coupon (4.5%) and maturity (2030) are placeholders for the credit display only, with no value effect. Base Y1 EPS of $12.79 is within ~1% of the ~$12.92 implied by the 7.71x forward P/E. There is no company guidance. AOCI is not modeled.

Relative value vs peers
MetricAXSACGLEGRNRWRBPeer medianvs median
P/E (TTM)7.1x7.9x8.1x6.0x15.5x8.0x−12%
P/E (forward)7.7x10.2x7.0x8.0x15.7x9.1x−15%
PEG3.2x2.9x0.6x1.0x2.9x2.0x+65%
P/B1.2x1.4x1.0x1.3x2.9x1.4x−13%
Dividend yield1.8%n/a2.1%0.5%2.5%2.1%−0.3pp
P/E (TTM)WRB15.5xEG8.1xACGL7.9xAXS7.1xRNR6.0x
P/E (forward)WRB15.7xACGL10.2xRNR8.0xAXS7.7xEG7.0x
PEGAXS3.2xWRB2.9xACGL2.9xRNR1.0xEG0.6x
P/BWRB2.9xACGL1.4xRNR1.3xAXS1.2xEG1.0x
Dividend yieldWRB2.5%EG2.1%AXS1.8%RNR0.5%

As of 2026-10-16. One source and one definition for every company: aggregator TTM and consensus-forward P/E; P/B on the source's book value per share. Not the model's own basis (common book ex-preferred over 73.8mm diluted shares; see the report's valuation table). Quotes are 2026-10-16 closing prices (4:00 PM ET) as shown on each page. Dashed line = peer median. Source: stockanalysis.com /stocks/<ticker>/statistics/, fetched 2026-10-16.

Notes. The source's PEG figures, based on its analyst growth estimates. ACGL pays no common dividend (source shows n/a). Omitted: EV-based multiples are not meaningful for insurers.

Scenario stress test

Reasoned from the bull/bear drivers above. The model column comes from the scenario overlays (Base case + shock).

Scenario Effect Mechanism Magnitude Model Δ value vs Base ($/sh)
S1 Fast equity crash − Risk-premium spike (cost of equity +1pp); small equity/alternatives book; no operating channel Med −$19.70
S2 Slow bear / recession − Exposures shrink; credit & political risk, surety and A&H losses rise; yields fall. ~23% of Base − Bear ($72.46), because recession is transitory while the bear case is a multi-year soft market plus reserve strengthening, and P&C claims are not recession-driven Med −$17.01
S3 Rapid rate shock ± Higher reinvestment yields vs a higher cost of equity; AOCI mark not modeled Med −$8.14
S4 Slow rate grind + Portfolio reinvests higher over years; modest cost-of-equity drag Med +$10.00
S5 Soft-landing cuts ± Lower yields vs a lower cost of equity Low +$5.96
S6 Recession-driven cuts − Yields fall, the insured base shrinks, credit lines lose Med −$15.55
S7a Credit liquidity shock − Risk-off; bond marks (AOCI, not modeled) proxied in the cost of equity Med −$19.70
S7b Slow default cycle − Credit & political risk, surety reinsurance and D&O losses; portfolio credit losses Med −$9.94
S8 Stagflation − Social and loss-cost inflation on casualty outruns pricing; higher yields only partly offset Med −$7.51
S9a Dollar spike 0 No material effect, not modeled; non-USD reserves broadly matched by assets — $0.00
S9b Dollar slide 0 No material effect, not modeled — $0.00
S10 Melt-up + Lower cost of equity Med +$12.36
S11 Energy supply shock − Marine, energy and political-violence/war losses (H1 2026 Middle East conflict losses $46mm) Low −$2.57
S12 Mega-cap/AI derating 0 No material effect, not modeled; no tech exposure of size, low beta — $0.00

No scenario moves Base value by more than ~14%, so nothing is labelled High. Currently active/on watch per the playbook: state.md lists S3 as partially active; the macro log for 2026-10-15 shows its pace legs back below threshold (10Y 5.10%). S8, S10 and S11 are on watch. S3, S8 and S10 are Med here, and S11 Low.

Model value change vs Base, by scenario
S1 Fast equity crash−$19.70S7a Credit liquidity shock−$19.70S2 Slow bear / recession−$17.01S6 Recession-driven cuts−$15.55S7b Slow default cycle−$9.94S3 Rapid rate shock−$8.14S8 Stagflation−$7.51S11 Energy supply shock−$2.57S9a Dollar spike$0.00S9b Dollar slide$0.00S12 Mega-cap/AI derating$0.00S5 Soft-landing cuts+$5.96S4 Slow rate grind+$10.00S10 Melt-up+$12.36

What would change the call

Upgrades if: not applicable at Buy. Conviction would firm if the Q3/Q4 insurance ex-cat accident-year ratio holds at or below ~85% while property rates keep falling. Downgrades if:

Watch items

Sources